Castle BiosciencesCSTL +6.07%72 Days Payable is 74.99 as of Mar. 2026, which is 14% above its 10-year median of 65.81. GuruFocus rates CSTL with a GF Score™ of 72/100 and a GF Value™ of $29.16 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Castle Biosciences ranks worse than 50.79% on this metric.
The historical rank and industry rank for Castle Biosciences's Days Payable or its related term are showing as below:
CSTL'
s Days Payable Range Over the Past 10 Years
Min: 41.49 Med: 65.81 Max: 88.48
Current: 65.68
During the past 9 years, Castle Biosciences's highest Days Payable was 88.48. The lowest was 41.49. And the median was 65.81.
CSTL's Days Payable is ranked worse than 50.79% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.87
vs CSTL: 65.68
Castle Biosciences's Days Payable
increased
from Mar. 2025 (42.90) to Mar. 2026 (74.99).
It may suggest that Castle Biosciencesdelayed paying its suppliers.
Castle Biosciences Days Payable Related Terms
Castle Biosciences Days Payable Historical Data
* Premium members only.
The historical data trend for Castle Biosciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Castle Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Castle Biosciences Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Castle Biosciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Castle Biosciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Castle Biosciences (CSTL) has a Days Payable of 74.99 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Castle Biosciences and its competitors. This is 14% above median its historical median of 65.81. Over the past decade, Castle Biosciences' Days Payable has ranged from 41.49 to 88.48. According to the industry distribution chart, Castle Biosciences ranks #97 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 50.8%.
Is Castle Biosciences' Days Payable too high?
Castle Biosciences' current Days Payable of 74.99 is 14% above median its 10-year median of 65.81. Over the past 10 years, this metric has ranged from a low of 41.49 to a high of 88.48. The Medical Diagnostics & Research industry median Days Payable is 68.87. Castle Biosciences' value of 74.99 is 8.9% above this industry median. Based on the distribution chart, Castle Biosciences ranks #97 out of 191 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Castle Biosciences has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Days Payable compare to FLGT and MYGN?
According to the Medical Diagnostics & Research industry distribution chart, Castle Biosciences ranks #97 out of 191 companies for Days Payable. This places Castle Biosciences in the lower half of its industry. The industry median Days Payable is 68.87. Castle Biosciences' value of 74.99 is 8.9% above this benchmark. Historically, Castle Biosciences' own Days Payable has ranged from 41.49 to 88.48 over the past decade. While the company's 10-year median is 65.81 vs. the industry median of 68.87, Castle Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 68.87, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Castle Biosciences's current Days Payable of 74.99 is 8.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Castle Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 68.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Castle Biosciences's current Days Payable is 74.99, which is 14% above median its own 10-year median of 65.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.16, compared to a current price of $24.21 — trading 17% below its estimated fair value. The current Days Payable is 74.99, which is 14% above median its 10-year median of 65.81 and 8.9% above the Medical Diagnostics & Research industry median of 68.87. Castle Biosciences' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Days Payable is 74.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Castle Biosciences (CSTL) Overvalued in 2026?
Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued.
The current stock price of $24.21 is trading 17% below its estimated GF Value™ of $29.16.
GuruFocus considers Castle Biosciences to be Modestly Undervalued.
Key valuation signals for CSTL:
Days Payable: 74.99 (14% above median its 10-year median of 65.81)
GF Value™: $29.16 vs. price of $24.21 (17% below fair value)
Industry Position: 8.9% above the Medical Diagnostics & Research median (#97 of 191)
No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
72GF Score
Get the complete analysis for CSTL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSTL has been successfully added to your 
